Log In
Print this Print this

PrandiMet (repaglinide/metformin)

Also known as: MetPrandin

  Manage Alerts
Collapse Summary General Information
Company Novo Nordisk A/S
DescriptionCombination of repaglinide, a short-acting beta-cell stimulating meglitinide and metformin
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentMarketed
Standard IndicationDiabetes
Indication DetailsTreat Type II diabetes
Regulatory Designation
Partner Shionogi & Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today